TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS

{
  "signal_id": "d0d6e208-0986-3806-513d-f2864e17f94e",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-08-27T06:00:00+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/tezspire-demonstrates-positive-phase-3-results-in-eosinophilic-esophagitis-across-both-co-primary-and-all-key-secondary-endpoints-302861404.html",
    "title": "TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS",
    "excerpt": "Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52 Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of TEZSPIRE THOUSAND OAKS, Calif. , Aug. 27, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca today announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE ® (tezepelumab-ekko) in patients living with eosinophilic esophagitis (EoE). TEZSPIRE demonstrated statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints at week 24 which were sustained through week 52. The co-primary endpoints were histologic remission and the frequency and severity of dysphagia (difficulty swallowing). The safety profile of TEZSPIRE was generally consistent with its approved indications. EoE is a chronic and progressive epithelial-driven inflammatory disorder of the esophagus affecting more than 470,000 people in the U.S., with the prevalence increasing five-fold since 2009. 1,2 Esophageal inflammation can lead to dysphagia, food impaction and esophageal narrowing. 2 For patients, the risk of food moving slowly or becoming stuck can make daily meals difficult and stressful. 3 Nearly half of patients, including adolescents, do not achieve adequate disease control with current first-line treatments, which...",
    "product": "TEZSPIRE",
    "summary": "Amgen and AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial for their drug TEZSPIRE® (tezepelumab-ekko) as a potential treatment for eosinophilic esophagitis (EoE).",
    "location": "Thousand Oaks, California, USA",
    "planning": true,
    "image_url": "https://mmx.prnewswire.com/media/MS352354/AMGEN-LOGO-V2.jpg?id=OA2915437&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "TEZSPIRE",
      "full_text": "TEZSPIRE ® (tezepelumab-ekko)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-08-27T06:00:00Z",
    "location_data": [
      {
        "city": "Thousand Oaks",
        "state": "California",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Amgen (NASDAQ: AMGN ) and AstraZeneca today announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE ® (tezepelumab-ekko) in patients living with eosinophilic esophagitis (EoE).",
    "related_company_name": "AstraZeneca",
    "related_company_domain": "astrazeneca.com"
  }
}

curl https://signals.autobound.ai/v1/signals/d0d6e208-0986-3806-513d-f2864e17f94e \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"amgen.com","limit":20}'